2 days Ago By ABMN Staff
KLP Kapitalforvaltning AS acquired a new stake in Theravance Biopharma, Inc. ( NASDAQ:TBPH – Free Report ) in the 4th quarter, Holdings Channel reports. The fund acquired 7,300 shares of the biopharmaceutical company’s stock, valued at approximately $69,000.
A number of other hedge funds have also made changes to their positions in the stock. Teacher Retirement System of Texas acquired a new stake in Theravance Biopharma in the fourth quarter worth approximately $103,000. SG Americas Securities LLC increased its position in shares of Theravance Biopharma by 21.
1% during the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,349 shares during the period. XTX Topco Ltd raised its stake in shares of Theravance Biopharma by 34.
5% in the 3rd quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 5,243 shares in the last quarter. Magnetar Financial LLC lifted its holdings in shares of Theravance Biopharma by 125.
8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company’s stock valued at $259,000 after buying an additional 15,328 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Theravance Biopharma during the third quarter valued at about $251,000.
Institutional investors and hedge funds own 99.10% of the company’s stock. Insider Buying and Selling at Theravance Biopharma In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st.
The shares were sold at an average price of $9.00, for a total transaction of $36,000.00.
Following the sale, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Insiders own 6.90% of the company’s stock.
Theravance Biopharma Stock Performance Theravance Biopharma ( NASDAQ:TBPH – Get Free Report ) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.
05) by ($0.26). Theravance Biopharma had a negative net margin of 78.
18% and a negative return on equity of 24.79%. The company had revenue of $18.
75 million for the quarter, compared to analysts’ expectations of $29.90 million. On average, research analysts forecast that Theravance Biopharma, Inc.
will post -1.09 earnings per share for the current year. Wall Street Analysts Forecast Growth Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.
00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $13.
75. Get Our Latest Stock Report on TBPH About Theravance Biopharma ( Free Report ) Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs.
Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. Further Reading Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. ( NASDAQ:TBPH – Free Report ). Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
